Clinical trials: Pituitary Tumors
Acromegaly, Pituitary Tumor
The Observational Study of Growth Hormone-secreting Pituitary Tumors
The major purpose of this study is to evaluate the changes of multiple organs in patients with growth hormone-secreting pituitary tumors before and after surgery.
- Trial name
- NCT01368133
- Where
- China
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Huashan Hospital
Basal Ganglia Germinoma, Diabetes Insipidus
A Study of Lower Radiotherapy Dose to Treat Children With CNS Germinoma
This phase II trial studies how well lower dose radiotherapy after chemotherapy (Carboplatin \& Etoposide) works in treating children with central nervous system (CNS) germinomas.
- Conditions
- Basal Ganglia Germinoma, Diabetes Insipidus, Germinoma, Pineal Region Germinoma
- Trial name
- NCT06368817
- Testing
- 3-Dimensional Conformal Proton Radiation Therapy, 3-Dimensional Conformal Radiation Therapy, Biospecimen Collection
- Where
- 115 sites in United States, Australia and 1 more
- Volunteers
- 240 people
- Sponsor
- Children's Oncology Group
Pituitary Adenoma, Prolactinoma
Comparison of Treatment Outcome of Cabergoline According to Target Prolactin Levels in Patients With Prolactinoma
The aim of this study is to investigate whether inhibition of serum prolactin levels below normal range during cabergoline administration may reduce the recurrence rate after drug withdrawal in patients with prolactinomas.
- Conditions
- Pituitary Adenoma, Prolactinoma, Pituitary Tumor, Recurrence Tumor
- Trial name
- NCT03457389
- Testing
- Cabergoline
- Where
- South Korea
- Volunteers
- 68 people
- Sponsor
- Seoul National University Hospital
Acromegaly
Pasireotide in Patients With Acromegaly Inadequately Controlled With First Generation Somatostatin Analogues
This is a phase IIIb multicenter, open-label; single arm study to evaluate the efficacy and safety of pasireotide LAR 40 mg and 60 mg in patients with inadequately controlled acromegaly with maximal approved doses of first…
- Trial name
- NCT02354508
- Testing
- Pasireotide LAR
- Where
- 50 sites in Argentina, Belgium and 13 more
- Volunteers
- 123 people
- Sponsor
- Novartis Pharmaceuticals
Pituitary Adenoma
Detection of Functioning Pituitary Microadenoma: PET/MRI Versus PET/CT
This is a prospective case-control study to compare the usefulness of 18F-FDG PET/MRI with that of 18F-FDG PET/CT in detection of functioning pituitary microadenomas.A single dose of 370 Mega-Becquerel (MBq) 18F-FDG will be…
- Trial name
- NCT03404414
- Testing
- 18F-FDG
- Where
- China
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Peking Union Medical College Hospital
Pituitary Diseases, Pituitary Neoplasms
Long Term Outcome Study in Patients With Pituitary Disorders
To determine the outcomes of patients with different pituitary disorders whether they are managed medically, surgically or expectantly.
- Trial name
- NCT03665064
- Volunteers
- 1,500 people
- Sponsor
- University of Alberta
Pituitary Adenoma
Proton Radiation Therapy for Pituitary Adenoma
The purpose of this study is to collect information from medical records to see what effects proton beam radiation has on pituitary tumors and analyze possible side effects.
- Trial name
- PI01 (NCT00798057)
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- University of Florida
Acromegaly
Dose Escalation of Octreotide-LAR as First-Line Therapy in Resistant Acromegaly
Epidemiological data indicate that patients with active acromegaly have reduced life expectancy because of cardiovascular (60%) and respiratory diseases (25%) mainly (1-10).
- Trial name
- HDacro (NCT00461149)
- Testing
- Octreotide-LAR
- Where
- Italy
- Volunteers
- 50 people
- Sponsor
- Federico II University
Cushing Disease
Fimepinostat, Combination HDAC and Pi3-kinase Inhibitor Tumor-Directed Therapy for Cushing Disease
Supported by the pre-clinical data (summarized in Research Strategy), the investigators propose that Fimepinostat is an ideal candidate drug in the treatment and intervention of patients with Cushing Disease.
- Trial name
- NCT05971758
- Testing
- Fimepinostat
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- University of California, Los Angeles
Acromegaly Due to Pituitary Adenoma, Difficult Intubation
Ultrasound in Predicting Difficult Intubation in Acromegaly Patients
This is a prospective observational study.The purpose of this study is to predict difficult intubation with ultrasonographic evaluation combined with preoperative physical examination in patients diagnosed with acromegaly and…
- Conditions
- Acromegaly Due to Pituitary Adenoma, Difficult Intubation, Airway Ultrasonography
- Trial name
- NCT07306325
- Testing
- observational study
- Where
- Turkey (Türkiye)
- Volunteers
- 34 people
- Sponsor
- Başakşehir Çam & Sakura City Hospital
Pituitary Adenoma
Heart Rate Variability (HRV) in Pituitary Adenoma
Several studies have been reported that heart rate is known to be associated with prognosis in chronic diseases and acute diseases.
- Trial name
- NCT03164148
- Testing
- T-REX TRI00A
- Where
- South Korea
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Seoul St. Mary's Hospital
Pituitary Adenoma, Pituitary Tumor
Electrophysiology of the Human Pituitary Gland
Measurment of electrophysiological properties of the human pituitary gland during removal of a pituitary adenoma. Assessment if these properties are sufficient for intra-operative identification of different tissues.
- Conditions
- Pituitary Adenoma, Pituitary Tumor, Diabetes Insipidus Cranial Type, Endocrine; Deficiency
- Trial name
- NCT05338125
- Testing
- Micro-electrode measurement
- Where
- Netherlands
- Volunteers
- 1 people
- Sponsor
- Leiden University Medical Center
Growth Hormone Deficiency
Growth Hormone Administration and Its Effects on Cardiovascular Risk Factors in Growth Hormone Deficient Women
The purpose of the study is to evaluate the effects of growth hormone replacement on women with growth hormone deficiency. Growth hormone deficiency means the body no longer produces growth hormone due to a tumor or some kind of…
- Trial name
- NCT00136032
- Testing
- Somatropin
- Where
- United States
- Volunteers
- 63 people
- Sponsor
- Massachusetts General Hospital
Pituitary Tumor
Effects of Total Intravenous Anesthesia With Propofol-remifentanil Versus Inhalational Anesthesia With Sevoflurane on Quality of Recovery in Patients Undergoing Transsphenoidal Surgery for Pituitary Tumor
A number of studies have compared the effects of total intravenous anesthesia(TIVA) versus inhalational anesthesia on perioperative period during transsphenoidal surgery.
- Trial name
- NCT02813044
- Testing
- total intravenous anesthesia (TIVA), inhalation anesthesia group
- Where
- South Korea
- Volunteers
- 82 people
- Sponsor
- Yonsei University
Primary Brain Tumors, Diffuse Glioma
Proton Versus Photon Radiotherapy in Adults With Primary Brain Tumors
This study will be done in adults with brain tumors having good prognosis requiring treatment with radiotherapy. The current practice for brain radiotherapy involves treatment using X rays (photon radiotherapy).
- Conditions
- Primary Brain Tumors, Diffuse Glioma, Meningioma, Pituitary Adenoma
- Trial name
- PRIDE (NCT06831461)
- Testing
- Proton Beam Therapy, Photon Radiotherapy
- Where
- India
- Volunteers
- 156 people
- Sponsor
- Tata Memorial Centre
In Vitro Fertilization, Polycystic Ovary Syndrome
Comparative Study of Long-acting and Short Acting Triptorelin in PCOS Patients Who Underwent IVF/ICSI
To test whether long-acting Triptorelin on pituitary down-regulation can improve the clinical pregnancy rate and reduces the incidence of ovarian hyperstimulation syndrome (OHSS) in infertile high-risk patients with polycystic…
- Trial name
- NCT02477566
- Testing
- Long-acting Triptorelin, Short-acting Triptorelin
- Where
- China
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Nanjing University
Acromegaly
Efficacy and Safety of Pasireotide Long Acting Release (LAR) Versus Octreotide LAR or Lanreotide Autogel (ATG) in Patients With Inadequately Controlled Acromegaly
This study will evaluate the efficacy and safety of pasireotide LAR 40 and 60 mg versus octreotide LAR or lanreotide ATG in patients with inadequately controlled acromegaly.
- Trial name
- PAOLA (NCT01137682)
- Testing
- Pasireotide, octreotide LAR 30mg, lanreotide ATG 120mg
- Where
- 60 sites in United States, Argentina and 16 more
- Volunteers
- 198 people
- Sponsor
- Novartis Pharmaceuticals
Locally Advanced Adrenal Gland Pheochromocytoma, Locally Advanced Paraganglioma
Radioactive Drug (177Lu-DOTATATE) for the Treatment of Locally Advanced, Metastatic, or Unresectable Rare Endocrine Cancers
This phase II trial studies how well 177Lu-DOTATATE works in treating patients with rare endocrine cancers that have spread from where they started to nearby tissue or lymph nodes (locally advanced), spread to other places in the…
- Conditions
- Locally Advanced Adrenal Gland Pheochromocytoma, Locally Advanced Paraganglioma, Metastatic Adrenal Gland Pheochromocytoma, Metastatic Paraganglioma
- Trial name
- NCT04106843
- Testing
- Lutetium Lu 177 Dotatate
- Where
- United States
- Sponsor
- M.D. Anderson Cancer Center
Pituitary Adenomas
The Effect of Chemoradiotherapy in Patients With Refractory Pituitary Adenomas
The purpose of this study was to determine whether radiotherapy combined with Temozolomide is more effective than radiotherapy alone in the treatment of patients with refractory pituitary adenomas.
- Trial name
- NCT04244708
- Testing
- Radiotherapy plus temozolomide
- Volunteers
- 150 people
- Sponsor
- Peking Union Medical College Hospital
Merkel Cell Carcinoma, Islet Cell Carcinoma
Antineoplaston Therapy in Treating Patients With Neuroendocrine Tumor That Is Metastatic or Unlikely to Respond to Surgery or Radiation Therapy
RATIONALE: Antineoplastons are naturally-occurring substances that may also be made in the laboratory. Antineoplastons may inhibit the growth of cancer cells.
- Conditions
- Merkel Cell Carcinoma, Islet Cell Carcinoma, Neuroendocrine Carcinoma, Pituitary Tumor
- Trial name
- NCT00003514
- Testing
- antineoplaston A10, antineoplaston AS2-1, alternative product therapy
- Where
- United States
- Sponsor
- Burzynski Research Institute